April 22, 2024

Digital/AI (R)Evolution in Drug Development & Manufacturing

Digital/AI (R)Evolution in Drug Development & Manufacturing

Digital/AI (R)Evolution in Drug Development & Manufacturing

Stadthaus Ulm
December 5, 2025

4th Joint Meeting of GBM & BioPharma Cluster South Germany

Dear colleagues and friends,

The successful series of joint events between the BioPharma Cluster South Germany and the German Society for Biochemistry and Molecular Biology (GBM) continues.

The 4th edition centres on the Digital (R)Evolution in Drug Development and Manufacturing, with a particular focus on artificial intelligence.

What are the opportunities for developing new drugs or improving production processes and therapies?
What methods are already in use in the pharmaceutical industry?
What will the future hold, and what challenges must we overcome?

The event will cover a broad range of expertise, from market developments and drug design to process simulation, optimisation and monitoring with perspectives ranging from basic and applied research to industrial study cases.

The event is designed for students, researchers, developers, and engineers from industry and academia, as well as anyone interested in this rapidly growing field, which already is and will continue to revolutionize the pharmaceutical industry.

At the event, we will offer all participants the opportunity for a vivid exchange and networking with speakers and other experts.
We would be pleased to welcome you on December 5th at the Stadthaus Ulm, located at Münster Platz, and look forward to an inspiring meeting with you!

Uwe Bücheler
(Senior Advisor Biopharmaceuticals and Chairman of the BioPharma Cluster South Germany)

register now

Our latest News

discover more
GalaTek GmbH and a:head bio AG Announce Strategic Collaboration to Automate Human Brain Organoid Workflows

GalaTek GmbH and a:head bio AG Announce Strategic Collaboration to Automate Human Brain Organoid Workflows

Vienna, Austria – October 22, 2025 – GalaTek GmbH, a leading innovator in laboratory automation technologies, and a:head bio AG, a pioneering biotech company specializing in human brain organoid research, today announced a strategic collaboration aimed at advancing the automation of brain organoid workflows. The partnership aims to integrate GalaTek’s advanced robotics and software platforms with […]

Clean Tech Innovation Day & Solar TAP Industry Day: Advanced solutions are needed

Clean Tech Innovation Day & Solar TAP Industry Day: Advanced solutions are needed

Heidelberg, Germany, October 22, 2025 – It’s all about a sustainable, smarter energy future: Clean Tech Innovation Day & Solar TAP Industry Day showed that this can only be achieved with a shared mission and vision. More than 70 participants from science, industry, and start-ups took the opportunity at the Heidelberg Congress Center to exchange […]

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Wayrilz (rilzabrutinib) as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp